Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H BRUCK

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
The Journal of Antimicrobial Chemotherapy|May 1, 1983
International clinical experience with azlocillinP Schacht, G Arcieri, H Bruck, et al.
Herz|December 28, 1999
Skin microcirculation in healthy subjects and patients with arteriosclerosisR R Wenzel, H Bruck, D Baumgart, et al.
Fortschritte Der Medizin|December 17, 1998
[How is sympathetic nervous system activity evaluated?]H Bruck, R F Schäfers, A E Daul, et al.
Herz|October 18, 2012
[Renal denervation: current state and future perspectives]K Kara, H Bruck, P Kahlert, et al.
British Journal of Clinical Pharmacology|August 8, 2001
Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in manR R Wenzel, J Rüthemann, H Bruck, et al.
Journal of Cardiovascular Pharmacology|May 11, 2001
Antihypertensive drugs and the sympathetic nervous systemR R Wenzel, H Bruck, G Noll, et al.
Journal of Hypertension|June 8, 2001
The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline-induced vasoconstriction: effects of the alpha2-receptor antagonist yohimbineH Bruck, M Gössl, R Spitthöver, et al.
Clinical Pharmacology and Therapeutics|April 6, 2007
Presynaptic alpha-2C adrenoceptor-mediated control of noradrenaline release in humans: genotype- or age-dependent?H Bruck, T Schwerdtfeger, M Toliat, et al.
Infection|January 1, 1988
Worldwide clinical data on efficacy and safety of ciprofloxacinP Schacht, G Arcieri, J Branolte, et al.
Deutsche Medizinische Wochenschrift (1946)|November 4, 2011
[Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment]F Mahfoud, O Vonend, H Bruck, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The Journal of Antimicrobial Chemotherapy|May 1, 1983
International clinical experience with azlocillinP Schacht, G Arcieri, H Bruck, et al.
Herz|December 28, 1999
Skin microcirculation in healthy subjects and patients with arteriosclerosisR R Wenzel, H Bruck, D Baumgart, et al.
Fortschritte Der Medizin|December 17, 1998
[How is sympathetic nervous system activity evaluated?]H Bruck, R F Schäfers, A E Daul, et al.
Herz|October 18, 2012
[Renal denervation: current state and future perspectives]K Kara, H Bruck, P Kahlert, et al.
British Journal of Clinical Pharmacology|August 8, 2001
Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in manR R Wenzel, J Rüthemann, H Bruck, et al.
Journal of Cardiovascular Pharmacology|May 11, 2001
Antihypertensive drugs and the sympathetic nervous systemR R Wenzel, H Bruck, G Noll, et al.
Journal of Hypertension|June 8, 2001
The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline-induced vasoconstriction: effects of the alpha2-receptor antagonist yohimbineH Bruck, M Gössl, R Spitthöver, et al.
Clinical Pharmacology and Therapeutics|April 6, 2007
Presynaptic alpha-2C adrenoceptor-mediated control of noradrenaline release in humans: genotype- or age-dependent?H Bruck, T Schwerdtfeger, M Toliat, et al.
Infection|January 1, 1988
Worldwide clinical data on efficacy and safety of ciprofloxacinP Schacht, G Arcieri, J Branolte, et al.
Deutsche Medizinische Wochenschrift (1946)|November 4, 2011
[Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment]F Mahfoud, O Vonend, H Bruck, et al.
Pageof 2